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Abstract
Background: In astrocytes, the inflammatory induction of Nitric Oxide Synthase type 2 (NOS2)
is inhibited by noradrenaline (NA) at the transcriptional level however its effects on specific
transcription factors are not fully known. Recent studies show that the activity of several
transcription factors including C/EBPβ, which is needed for maximal NOS2 expression, is
modulated by conjugation of the small molecular weight protein SUMO. We examined whether
the expression of SUMO Related Genes (SRGs: SUMO-1, the conjugating enzyme Ubc9, and the
protease SENP1) are affected by inflammatory conditions or NA and whether SUMO-1 regulates
NOS2 through interaction with C/EBPβ.
Methods:  Bacterial endotoxin lipopolysaccharide (LPS) was used to induce inflammatory
responses including NOS2 expression in primary astrocytes. The mRNA levels of SRGs were
determined by QPCR. A functional role for SUMOylation was evaluated by determining effects of
over-expressing SRGs on NOS2 promoter and NFκB binding-element reporter constructs.
Interactions of SUMO-1 and C/EBPβ with the NOS2 promoter were examined by chromatin
immunoprecipitation assays. Interactions of SUMO-1 with C/EBPβ were examined by
immunoprecipitation and Western blot analysis and by fluorescence resonance energy transfer
(FRET) assays.
Results: LPS decreased mRNA levels of SUMO-1, Ubc9 and SENP1 in primary astrocytes and a
similar decrease occurred during normal aging in brain. NA attenuated the LPS-induced reductions
and increased SUMO-1 above basal levels. Over-expression of SUMO-1, Ubc9, or SENP1 reduced
the activation of a NOS2 promoter, whereas activation of a 4 × NFκB binding-element reporter
was only reduced by SUMO-1. ChIP studies revealed interactions of SUMO-1 and C/EBPβ with C/
EBP binding sites on the NOS2 promoter that were modulated by LPS and NA. SUMO-1 co-
precipitated with C/EBPβ and a close proximity was confirmed by FRET analysis.
Conclusion:  Our results demonstrate that SUMOylation regulates NOS2 expression in
astrocytes, and point to modification of C/EBPβ as a possible mechanism of action. Targeting the
SUMOylation pathway may therefore offer a novel means to regulate inflammatory NOS2
expression in neurological conditions and diseases.
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Background
Nitric oxide generated by Nitric Oxide Synthase type 2
(NOS2, also termed iNOS) contributes to disease progres-
sion in a variety of neurological diseases and conditions.
NOS2 is the calcium-independent isoform of the NOS
family whose expression is generally restricted, but is
highly and rapidly induced upon activation by a variety of
stimuli, among them cytokines and bacterial endotoxin
lipopolysaccharide (LPS). Several investigators have con-
firmed NOS2 expression in primary astrocytes upon
inflammatory induction [1-4] as well as in neurological
diseases including Multiple Sclerosis (MS), its animal
model EAE [5-7], cerebral ischemia [8], and Alzheimer's
disease [9-11].
Transcription of the NOS2 gene has been shown to
require activation of transcription factor NFκB [12,13];
however in many cell types activation of CCAAT/
enhancer-binding proteins (C/EBPs) are necessary for
maximal NOS2 expression [14-18]. The C/EBPs constitute
a family of basic leucine-zipper transcription factors
which form homo and hetero dimers that bind to similar
cis-regulatory elements with varying affinities [19,20]. The
leucine-zipper motif constitutes the dimerization domain
of the C/EBP protein whereas the basic region is the DNA
contact area that determines binding specificity. C/EBP
isoforms include C/EBPα, C/EBPβ (also known as NF-IL6,
IL-6-DBP, LAP, AGP/EBP, or CRP2), C/EBPδ (also called
CRP3, CELF, or NF-IL6b), C/EBPγ (IgEBP), C/EBPε
(CRP1), and C/EBPζ (CHOP). C/EBPβ is itself composed
of several variants due to use of alternative translation
start sites, resulting in C/EBPβ1 (the full length protein,
also called LAP*), C/EBPβ2 (LAP, shorter by 23 amino
acids versus LAP*), and C/EBPβ-20 (LIP, which lacks the
transactivation domain and is considered to be a domi-
nant negative isoform).
The expression of NOS2 has been shown to be regulated
by the neurotransmitter noradrenaline (NA), via activa-
tion of beta-adrenergic receptors and a resulting increase
in cAMP levels [21-23]. Although the effect of NA occurs
at the transcriptional level, it does not inhibit the activa-
tion of NFκB or its binding to DNA [24]. A 27 bp region
of the NOS2 promoter containing an almost consensus
(6/7 identities) CRE site and a consensus binding site for
C/EBP was shown to be critical for inhibition by NA rais-
ing the possibility of regulation through these transcrip-
tion factors [25].
The activity of C/EBP family members, like many tran-
scription factors and co-factors, is regulated by the protein
Small Ubiquitin like Modifier (SUMO) [26-29]. The cov-
alent binding of SUMO to acceptor sites on target proteins
involves several steps starting with conversion of the pre-
cursor to mature SUMO by a C-terminal hydrolase
(SENP) [30]. The SUMO Activating Enzyme (SAE) E1
transfers SUMO to conjugating enzyme E2 (Ubc9) which
then catalyzes the formation of an isopeptide bond
between the C-terminal glycine of SUMO and the ε-amino
group of a target lysine. The majority of target lysines are
within SUMO consensus motifs, however proteins with-
out such motifs can also be SUMOylated. SUMO E3
ligases (PIAS, RanBP2) increase the efficiency of the reac-
tion possibly also facilitating SUMOylation of targets
lacking the consensus motif. The proteases (SENP)
involved in maturation are also responsible for the
removal of SUMO from substrates [31-33].
Recent reports implicating SUMOylation in regulation of
inflammation [34-36] as well as NOS2 transcription [37]
combined with our findings that effects of NA on NOS2
expression most likely involve C/EBPβ prompted us to
investigate whether SUMO-1 is involved in regulation of
NOS2 transcription through modification of C/EBPβ. In
this study we show that the expression of SUMO-1 and
two critical SUMOylation enzymes (collectively referred
to here as SRGs for SUMO Related Genes) as well as C/
EBPβ are regulated under pro- and anti-inflammatory
conditions, and that these genes modulate NOS2 pro-
moter activation. Our data further support that interac-
tions of SUMO-1 and C/EBPβ occur at the NOS2
promoter and are important for modulating NOS2 tran-
scription.
Materials and methods
Cells and treatments
Primary astrocytes were prepared from cerebral cortices of
postnatal day 1 Sprague-Dawley rats as previously
described [1]. After 2 weeks of growth in complete
medium (DMEM, 10% FBS, 1% penicillin/streptomycin)
the cultures consisted of 95–98% astrocytes. C6 rat glioma
cells were grown in complete medium. Cell cultures at
80–90% confluency, were transferred to DMEM with 1%
FBS and antibiotics and treated with LPS (1 μg/ml) and/or
NA (30 μM) for induction or modulation of NOS2. Luci-
ferase activity assays, chromatin and protein immunopre-
cipitations, and mRNA analysis were conducted 4 hr after
treatments. Transfections were done with cells at 50–60%
confluency and treatments were initiated 40 hr after trans-
fection.
mRNA analysis
Total cytoplasmic RNA was prepared from primary astro-
cytes or cerebral cortices of mice using TRIZOL reagent
(Invitrogen, Carlsbad, CA); aliquots were converted to
cDNA using random hexamer primers and mRNA levels
estimated by reverse transcription-PCR (RT-PCR). The
primers used for NOS2 were forward 5'-GGAGAAG-
GGGACGAACTCAGT-3' and reverse 5'-GCATTGGAAGT-
GAAGCGTTTC-3'; for SUMO-1 were forward 5'-Journal of Neuroinflammation 2009, 6:12 http://www.jneuroinflammation.com/content/6/1/12
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TTTCATGTGTGCACAGAGAGGCCA-3' and reverse 5'-
AGTCCAGGAGTGAAGCAACCACAT-3'; for Ubc9 were
forward 5'-AAGGAGGCTTGTTCAAGCTACGGA-3' and
reverse TTTGATGGTGATAGCTGGCCTCCA-3'; for SENP-
1 were forward 5'-ACACTGGAGCCTGGTGGTAATTGA-3'
and reverse 5'-TGTACTGCTTCCACTCCAAAGGGT-3'; for
C/EBPβ were forward 5'-ATGCAATCCGGATCAAACGT-
GGCT-3' and reverse 5'-TTTAAGTGATTACTCAG-
GGCCCGGCT-3'; for β-actin were forward 5'-
CCTGAAGTACCCCATTGAACA-3' and reverse 5'-
CACACGCAGCTCATTGTAGAA-3'. PCR conditions were
35 cycles of denaturation at 94°C for 10 sec; annealing at
61°C for 15 sec; and extension at 72°C for 20 sec; fol-
lowed by 2 min at 72°C. For the data shown in figure 1,
changes in mRNA levels were estimated by semi-quantita-
tive means. The PCR products were separated through
agarose gels, product band intensities for SUMO-1, Ubc9,
NOS2, C/EBPβ, and β-actin quantified by ImageJ soft-
ware, and the mRNA levels for target genes normalized to
the values measured for β-actin in the same samples. For
the data shown in figure 2, changes in mRNA levels were
estimated by quantitative PCR (QPCR) in the presence of
SYBR Green (1:10,000 dilution of stock solution; Molecu-
lar Probes, Invitrogen) carried out in a 20-μl reaction in a
Corbett Rotor-Gene (Corbett Research, QIAGEN, Valencia
CA). Relative mRNA levels were calculated from the take-
off cycle (Ct) of reactions using manufacturer's included
software, and normalized to values measured for β-actin
mRNA in the same samples to account for any differences
in sample quality or tube to tube variability. QPCR meas-
urements did not show any significant change in the Ct
values for β-actin, nor for those measured for α-tubulin, in
brain cortical RNA samples from mice aged 3 to 15
months (data not shown). QPCR products were separated
by electrophoresis through 2% agarose gels containing 0.1
μg/ml ethidium bromide to verify production of correctly
sized products.
Plasmids
Luciferase reporter plasmids were constructed with NOS2
promoter fragments as described [25]. The pGL3-2.2 plas-
mid contains 2.2 kB upstream of the start site of the rat
NOS2 promoter; pGL3-CREB extends upstream to base -
187 relative to the start site; and pGL3-κB extends
upstream to base -130. HA-SUMO-1, and myc-Ubc9
expression plasmids were a gift of Dr. Edward Yeh (Ander-
son Cancer Center, Houston, TX) and pMSV-C/EBPβ a gift
of Dr. Steven J. Ackerman (University of Illinois, Chicago,
IL). pSV(X)-C/EBPβ was obtained from Addgene (Cam-
bridge, MA; plasmid 13393; donated by Dr. Richard
Schwartz). YFP-SUMO-1 and CFP-RanGAP1 were a gift of
Dr Frauke Melchior (Georg-August-Universitaet, Goettin-
gen, Germany). To construct CFP-C/EBPβ, RanGAP1 was
excised using Bgl2 and BamH1 from the CFP-plasmid and
replaced with the C/EBPβ insert excised using BamH1
from pSV(X)-C/EBPβ.
Transfections
Stable transfectants of NOS2 constructs in pGL3 vector
were generated as previously described [25]. Transient
transfections were conducted using Effectene reagent
(QIAGEN) according to manufacturers instructions. The
phRG-TK vector (Promega, Madison, WI) was co-trans-
Effect of inflammatory activation on SRGs, NOS2, and C/ EBPβ mRNA levels in astrocytes Figure 1
Effect of inflammatory activation on SRGs, NOS2, 
and C/EBPβ mRNA levels in astrocytes. Primary rat 
astrocytes were treated with LPS (L) or LPS+NA (LN) for 4 
hours. Total mRNA was converted to cDNA, and amplified 
using primers for (A) SUMO-1, Ubc9, and SENP1; and (B) 
NOS2 and C/EBPβ. PCR products were separated through 
2% agarose gels, and the band intensities were quantified 
using ImageJ software. The data is the mRNA level measured 
in treated samples compared to non-treated control sam-
ples, and normalized to values for β-actin measured in the 
same samples. Data is the mean ± sd of n = 3 samples in each 
group. **, p < 0.01; ***, p < 0.001 L vs control or LN vs L 
(unpaired t-test).
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fected as an internal control reporter to experimental
reporter constructs at a ratio of 1:50 (w/w).
Luciferase activity assays
Luciferase activity in stably transfected cells was deter-
mined using Bright-Glo Luciferase Assay System
(Promega) in a microplate luminometer (Rosys-Anthos,
Anthos, Durham, NC, USA). Luciferase activity in tran-
siently transfected cells was determined using Dual-Luci-
ferase Reporter Assay System (Promega) in a single sample
luminometer (Femtomaster FB12, Zylux, Huntsville, AL).
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation (ChIP) experiments
were conducted according to a protocol developed at the
University Health Network Microarray Centre http://
www.microarrays.ca/support/PDFs/
ChIP_Beads_Sept2008.pdf, Toronto, Canada). Briefly,
cells grown in 10 cm plates to 80–90% confluency were
treated as described above, proteins were cross linked to
DNA using 1% formaldehyde (37°C for 10 min), then
cells were lysed in buffer containing 1% SDS, 10 mM
EDTA and 50 mM Tris, pH 8. Chromatin was sheared by
sonication on ice at setting 6 (Sonic Dismembrator, Fisher
Scientific, Pittsburgh, PA) for 20 s, 8× with 2 min inter-
vals. Supernatants containing chromatin fragments
(mostly 600 bp) were incubated with 0.5 μg/ml mouse
monoclonal IgG2a (sc-7962 directed against C-terminus
amino acids 199–345 of human C/EBPβ and which
detects all C/EBPβ isoforms and to a lesser extent C/EBPα,
δ, or ε, Santa Cruz Biotechnology, Santa Cruz, CA); 0.5
μg/ml mouse monoclonal IgG (anti-GMP1, which recog-
nizes the 17 kDa unconjugated SUMO-1 as well as
SUMO-1 ligated to target proteins, Zymed, Invitrogen) or
no antibody (control) overnight. Immunocomplexes
were precipitated with Protein A Sepharose beads in the
presence of 1 mg/ml yeast tRNA as blocking agent. Precip-
itates were subjected to several washes and then protein-
DNA complexes eluted from beads by incubation in 0.1 M
NaHCO3 containing 1% SDS. DNA: protein cross-links
were reversed by incubating samples at 65°C for 5 hr in
the presence of 200 mM NaCl and 20 μg/ml RNAse A,
proteins digested with proteinase K (0.3 mg/ml), and
DNA recovered using QiaQuick (QIAGEN) PCR purifica-
tion columns. C/EBPβ binding site containing segments
of the rat NOS2 promoter were amplified using primers -
425F 5'-TCCACACTGCCAGTAATCCACAGA-3' and -
107R 5'-CCAGTAGGGTGTGCAAGTTAG-3' and primers -
127F 5'-GCTAACTTGCACACCCTACTG-3' and 61R 5'-
TGGCTGAGAAGTTTCAAACCAGCG-3' For sequential
ChIP experiments precipitated chromatin was eluted from
the protein A/G-sepharose beads (Santa Cruz) with 10
mM DTT, diluted 20× with 20 mM Tris (pH 8) containing
150 mM NaCl, 2 mM EDTA, 1% TritonX-100 and sub-
jected to a second round of immunoprecipitation.
Immunoprecipitation and western blot analysis
Astrocytes grown in 6 cm plates were treated as described
above. Cells were lysed in β-glycerophosphate buffer con-
taining 2% SDS as described [38]. Immunoprecipitations
were conducted with 1 μg/ml mouse monoclonal IgG2a
(sc-7962, Santa Cruz); after lysates were diluted 20× with
lysis buffer without SDS. Precipitated proteins were sepa-
rated by 10% SDS-PAGE and transferred onto PVDF
membranes. Membranes were blocked with 5% milk in
TBS-T and probed with rabbit polyclonal anti-SUMO-1
antibody (0.87 μg/ml final concentration) raised against
mature human SUMO-1 [39], a gift of Dr. John M. Hallen-
beck, NINDS/NIH, Bethesda, MD).
Fluorescence Resonance Energy Transfer analysis (FRET)
Primary astrocytes on gelatin coated coverslips were co-
transfected with YFP-SUMO-1 and CFP-C/EBPβ expres-
sion plasmids. 24 hr after transfection cells were fixed
with 3.7% formaldehyde. FRET analysis was conducted
using LSM510 Meta system (Zeiss, Thornwood, NY).
Emission spectra were obtained from cells co-expressing
YFP-SUMO-1 and CFP-C/EBPβ as three dimensional
image stacks by laser scanning microscopy using non
bleaching intensities of 458 nm for CFP and 514 nm for
YFP. Reference spectra obtained from cells expressing only
CFP-C/EBPβ or only YFP-SUMO-1 were used for separa-
tion of the emission spectra by linear un-mixing software
of the LSM510 Meta system. In cells expressing both fluor-
ophores the acceptor YFP-SUMO-1 was photobleached in
defined regions of interest (ROIs) using 100% power of
Changes in SRG, NOS2, and C/EBPβ mRNA levels during  aging Figure 2
Changes in SRG, NOS2, and C/EBPβ mRNA levels 
during aging. Cerebral cortices of C57BL/6 mice of the 
indicated ages were sonicated briefly in Trizol reagent, total 
mRNA extracted, and converted to cDNA. Aliquots were 
analyzed by QPCR for levels of (A) SUMO-1 and Ubc9; and 
(B) NOS2 and C/EBPβ mRNAs. The data are mean ± sd of 3 
mice per age group, normalized to values for β-actin mRNA 
measured in the same samples. There was a significant 
decrease in SUMO-1 and Ubc9, and a significant increase in 
NOS2 and C/EBPβ over time (P < 0.01, 1-way ANOVA); *, p 
< 0.05; **, p < 0.01 vs 3-month samples (Bonferroni multiple 
comparison post hoc tests).
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the 514 nm laser line and the lack of fluorescence reso-
nance energy transfer to the acceptor in those regions was
observed as an increase in the donor (CFP-C/EBPβ) fluo-
rescence.
Statistical analysis
Group data shown in figures 1 and 3 were analyzed by
unpaired T-tests; QPCR data at different ages shown in fig-
ure 2 was analyzed by 1 way ANOVA and Bonferroni mul-
tiple comparison post hoc analyses; FRET data shown in
figure 4 was analyzed by non-parametric paired T-test of
CFP fluorescence measured before and after photobleach-
ing in the same ROI. Significance was taken at p values <
0.05.
Results
SRG expression is modulated by inflammatory stimulus 
and NA
The mRNA levels of the SRGs SUMO-1, Ubc9, and SENP1
were determined under naïve or inflammatory conditions
in primary astrocytes (Figure 1). Treatment with LPS
resulted in an approximately 50% decrease in Ubc9 and
SENP1 mRNA levels, and an approximately 30% decrease
in SUMO-1 mRNA levels compared to untreated (control)
cells. The presence of NA altered the LPS effect on these
enzymes and SUMO-1 to varying degrees. The inhibitory
effect of LPS on SENP1 was attenuated by approximately
50%, whereas the level of Ubc9 mRNA was restored back
to untreated levels. NA not only reversed the LPS effect on
SUMO-1 mRNA levels but caused an increase of approxi-
mately 20% (Figure 1A). The inflammatory effect of LPS
was verified by an increase in NOS2 mRNA (Figure 1B).
C/EBPβ mRNA levels were also increased by LPS, consist-
ent with its involvement in inflammatory activation. As
previously shown [23], co-treatment with NA reduced the
effect of LPS on NOS2 but had no effect on C/EBPβ mRNA
levels (Figure 1B).
SRG expression decreases with aging
During aging, a reduction in brain NA levels occurs, which
could contribute to increased neurological damage [40].
Analysis of expression of SUMO-1 and the conjugating
enzyme Ubc9 mRNA levels (Figure 2A) revealed a signifi-
cant age-dependent change in SUMO-1 and Ubc9 mRNA
levels in the frontal cortex of wild type C57BL/6 mice
between 3 and 15 months of age, with values at 15
Effect of increasing SRG expression on promoter activity Figure 3
Effect of increasing SRG expression on promoter 
activity. C6 cells stably transfected with pNFκB (4 × NFκB 
binding-element) or pGL3-2.2 (2.2 kB NOS2 promoter 
sequence) luciferase reporter plasmids were transiently 
transfected with SUMO-1, Ubc9, or SENP1 expression plas-
mids or with vector only (pcDNA3). After 40 hours cells 
were treated with LPS for 4 hours and luciferase activity 
measured. The data shows relative luciferase activity of 
treated versus untreated cells, and is the mean ± sd of 3 
independent experiments. *, p < 0.05; **, p < 0.01 vs vector 
(unpaired t-test).
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Sumoylation of C/EBPβ in astrocytes Figure 4
Sumoylation of C/EBPβ in astrocytes. Primary rat astro-
cytes were co-transfected with YFP-SUMO-1 and CFP-C/
EBPβ expression plasmids. After 24 hr the cells were fixed, 
and cells co-expressing YFP-SUMO-1 and CFP-C/EBPβ were 
subjected to FRET analysis. (A) Representative image of CFP 
and YFP fluorescence after linear un-mixing of emission spec-
tra and merged image showing the region of interest (ROI) 
analyzed. (B) FRET data after acceptor photobleaching of the 
ROI indicated ("1") in panel A, showing an increase in CFP 
fluorescence coincident with a decrease in YFP fluorescence. 
(C) CFP fluorescence of ROIs measured in 7 different cells 
before (open bars) and after (filled bars) acceptor photob-
leaching. "Ave" mean ± s.e (n = 7) of CFP fluorescence. *, p < 
0.05 after versus before, non parametric paired T-test.
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months reduced about 70% compared to the values meas-
ured at 3 months. During this time, there was also a sig-
nificant age-dependent change in C/EBPβ and NOS2
mRNA levels, with increases of 3- to 5-fold measured
between 3 and 15 months of age (Figure 2B) suggesting an
age-dependent increase in overall inflammatory status.
Over-expression of SRGs modulate NOS2 promoter 
activity
To determine if SUMOylation was involved in inflamma-
tory activation, rat C6 glioma cells stably transfected with
luciferase reporter constructs pNFκB (4 × NFκB binding-
element) or pGL3-2.2 (containing the 2.2 κB NOS2 pro-
moter sequence)were transiently transfected with SRG
expression plasmids and the promoter activation by LPS
was determined (Figure 3). Over-expression of SUMO-1
diminished the LPS-dependent increase in activity of both
constructs. Increasing Ubc9 levels did not affect pNFκB
activity but decreased pGL3-2.2 activity. Similarly, over-
expressing SUMO protease SENP1 did not affect pNFκB
but diminished pGL3-2.2 activity.
Effects of LPS and NA on association of C/EBP  and 
SUMO-1 with the NOS2 promoter
The involvement of C/EBPβ and SUMO-1 in NOS2 tran-
scription was further investigated using ChIP assays to
detect the association of these proteins with regions of the
NOS2 promoter containing either the C/EBP-2 or the C/
EBP-3 site (Figure 5A). C/EBPβ was found associated with
both the C/EBP-2 and C/EBP-3 sites under all conditions;
however binding to C/EBP-2 was increased by treatment
with LPS plus NA (Figure 5B). SUMO-1 was detected at
both sites, although a stronger signal was obtained with
the fragment of the NOS2 promoter containing the C/
EBP-3 site (Figure 5C). Treatment with LPS reduced asso-
ciation of SUMO-1 with this site while addition of NA
restored it (or prevented that loss). Re-precipitation of
SUMO-1 interacting fragments with anti-C/EBPβ anti-
body showed that under all conditions, the C/EBP-3 site
also interacted with C/EBPβ (Figure 5C, bottom panel).
In contrast there was little evidence for simultaneous asso-
ciation of both SUMO-1 and C/EBPβ at C/EBP-2 site. An
interaction of SUMO-1 with C/EBPβ was confirmed by
Western blots which showed that SUMO-1 co-immuno-
precipitated with C/EBPβ (Figure 5D), and this interac-
tion was increased by the presence of NA.
Interaction of SUMO-1 and C/EBP
The possibility that C/EBPβ can be SUMOylated in pri-
mary astrocytes was further tested using FRET analysis.
Primary astrocytes were co-transfected with expression
plasmids encoding CFP-tagged C/EBPβ and YFP-tagged
SUMO-1 (Figure 4A), and FRET measured by the increase
in donor fluorescence (CFP-C/EBPβ) after photobleach-
ing of the acceptor molecule (YFP-SUMO-1) (Figure 4B).
Acceptor photobleaching of selective ROIs in cells express-
ing both fluorophores resulted in a significant increase of
donor fluorescence (Figure 4C), consistent with a close
proximity of C/EBPβ and SUMO-1 since FRET can only
occur between a donor and acceptor pair at distances less
than 10 nm.
Discussion
In this study we demonstrate that SUMO-1 and the
enzymes Ubc9 and SENP1 of the SUMOylation process
are expressed in primary astrocytes and that their expres-
sion is modified under inflammatory conditions. We also
show that over-expressing these proteins modifies the
astrocyte response to LPS, demonstrating a functional role
for SUMOylation in astrocytes. To our knowledge this is
the first report to characterize SUMO-1 and SRGs in astro-
cytes, confirming the existence and functionality of this
important signaling pathway in one of the most abundant
cell types in brain.
Our data shows that pro-inflammatory conditions that are
induced by LPS or during normal aging, and as evidenced
by a significant increase in the expression of NOS2 as well
as C/EBPβ, decrease the expression levels of SUMO-1,
Ubc9 and the protease SENP1, suggesting an anti-inflam-
matory role for SUMO-1 in brain. Although a decrease in
Presence of C/EBPβ and SUMO-1 on the NOS2 promoter Figure 5
Presence of C/EBPβ and SUMO-1 on the NOS2 pro-
moter. Primary astrocytes were treated with nothing (C), 
LPS (L), or LPS+NA (LN) for 4 hours, then ChIP analysis 
conducted. (A) Two fragments of the rat NOS2 promoter 
containing the proximal C/EBP-2 (top) or C/EBP-3 (bottom) 
binding sites were amplified by PCR after immunoprecipita-
tion using (B) anti-C/EBPβ antibody or (C) anti-SUMO-1 
antibody alone or followed by anti-C/EBPβ antibody. The 
products were separated through 2% agarose gels and their 
accuracy was verified by comparison to input DNA ("in", 5% 
of total input). The images shown are inverted versions 
(Adobe Photoshop) of the original gel images and are repre-
sentative of results obtained in 2 separate experiments. (D) 
Lysates of astrocytes treated as indicated above were immu-
noprecipitated (IP) with anti-C/EBPβ antibody and Western 
blot (W) of the samples was probed with anti-SUMO-1 anti-
body.
α-C/EBPβ
(A)
α-C/EBPβ
CL L N C L LN in in
(C)
α-SUMO-1
(B)
C
/
E
B
P
-
2
C
R
E
-107 -425
N
F
-
κ
B
C
/
E
B
P
-
3
-127 +61
α-C/EBPβ
(D)
CL L N
IP : α-C/EBPβ
W : α-SUMO-1Journal of Neuroinflammation 2009, 6:12 http://www.jneuroinflammation.com/content/6/1/12
Page 7 of 10
(page number not for citation purposes)
SENP1 expression might be expected to promote inflam-
mation (by reducing overall SUMOylation status), this
enzyme is also involved in SUMO-1 maturation [41]. The
fact that NA, an anti-inflammatory neurotransmitter,
attenuates the effects of LPS on both the SRGs and NOS2
further supports an anti-inflammatory role of SUMO-1,
and suggests that SUMOylation contributes to NA effects.
Reduction in NA levels that occur during aging [40] could
therefore contribute to the age-dependent decrease in
SRGs.
In our experiments NOS2 promoter activity was decreased
when SUMO-1, Ubc9, or SENP1 were over-expressed (Fig-
ure 3), suggesting an inhibitory role in primary astrocytes.
SUMO-1 over-expression also decreased the activity of a
pNFκB reporter plasmid that can only bind NFκB, which
itself is not a SUMO target, therefore implying modula-
tion of NFκB activity through interaction with other fac-
tors such as NEMO, IKK, or the inhibitory IκBα protein.
Since NA increases both SRGs as well as IκBα [25], this
raises the possibility that SUMOylation of IκBα contrib-
utes to the inhibitory effects of NA. However, the fact that
over-expression of Ubc9 or SENP1 did not affect pNFκB
activity suggests that their ability to inhibit NOS2 involves
SUMOylation of proteins other than NFκB-related mole-
cules.
The increase we observed in C/EBPβ mRNA levels caused
by inflammatory stimuli are in accordance with previous
studies [42-44]. Interestingly, and as we have shown
before for the activation of NFκB [25], NA did not affect
C/EBPβ mRNA levels although it reduced NOS2 mRNA.
Several reports have shown that C/EBPβ activity is con-
trolled by modulating its binding to DNA [45] and in
many cell types NFκB and C/EBPβ co-operate in regulat-
ing NOS2 transcription [46,47]. This suggests that NA
could inhibit NOS2 activation by altering the interaction
of C/EBPβ with DNA and/or NFκB.
Although some reports suggest that other C/EBPs can be
involved in the regulation of NOS2 expression [17,48] in
this paper we have focused attention on the C/EBPβ iso-
form since in most studies NOS2 transcription has been
shown to involve C/EBPβ. In rat C6 glioma cells, NOS2
induction by over-expression of MAPKs was blocked by a
dominant negative form of C/EBPβ [49]. In human astro-
cytes, activation by the HIV-1 tat protein induced C/EBPβ
expression and a dominant negative C/EBPβ blocked NO
production [50]. In smooth muscle cells induction of
NOS2 was accompanied by binding of C/EBPβ to the pro-
moter [51], and in kidney cells, supershift assays revealed
only the presence of C/EBPβ on the NOS2 promoter,
when induced by LPS and IFNγ [52]. In liver cells, overex-
pression of the C/EBPβ-20 inhibitor LIP suppressed activ-
ity of the human NOS2 promoter [18]. Other inhibitors
have also been shown to reduce NOS2 expression associ-
ated with a decrease in C/EBPβ levels or binding to the
promoter [15,53,54].
Although several roles for SUMOylation in brain have
been reported, there are limited studies describing the
ability of SUMOylation to regulate brain inflammation.
SUMOylation can have pro- or anti-inflammatory actions,
depending on the specific SUMO isoform that is conju-
gated and the target protein. SUMO-1 levels were shown
to be low in Parkinson's disease and Alzheimer's disease
(AD) samples [55]; while SUMO-2/3 was detected at high
levels in cortex after cerebral ischemia [38]. Transfection
studies have shown that SUMOylation of amyloid precur-
sor protein reduced Aβ production in human neurons
[56] and in HeLA cells [57]; and that SUMO-1 modifica-
tion increases human superoxide-dismutase-1 stability
and aggregation [58]. The protein IRAK1 (interleukin-1
receptor associated kinase type 1) which transduces IL1
signaling and immune responses of Toll-like receptors is
SUMOylated in brain, which could influence its ability to
modulate inflammation [59].
SUMOylation is known to modulate transcription factor:
DNA interactions [60,61] and in many cases has been
shown to attenuate inflammatory responses [35,36,62].
SUMOylation of JunB modifies its ability to induce
cytokine expression [63], SUMOylation of PPARγ
increases it's interactions with the NCoR co-repressor and
prevents inflammatory responses [37], SUMO-1 can mod-
ify several members of the NFκB signaling pathway,
including NEMO (NFκB essential modulator) necessary
for NFκB activation [64], as well as the inhibitory IκBα
protein [34,65] and its kinase IKK [66]; and SUMOylation
of STAT1 reduces IFN-dependent, STAT1 mediated tran-
scription [67]. SUMOylation of C/EBPs has been shown
to modulate transcription [26-29,68,69], and in many
cases associated with reduced activity. An increase in
SUMOylated C/EBPβ was shown to be involved in reduc-
tion of COX2 expression [70], and SUMOylation of C/
EBPβ reduces albumin transcription [68]. Similarly, the
synergic control elements of C/EBPα are believed to
require SUMOylation for activity [29]. We therefore we
considered the possibility that NA altered CEBP/β activity
through SUMOylation.
There are several binding sites for members of C/EBP fam-
ily on the rat NOS2 promoter, two of which are located
close to the proximal NFκB binding site (C/EBP-2, located
upstream; C/EBP-3, located downstream). ChIP results
show that LPS treatment is associated with decreased lev-
els of SUMO-1 associated with C/EBP-3; and that NA
restores those levels (or prevents the LPS-induced loss).
This suggests that SUMO-1 at this site exerts suppressive
effects. We observed that C/EBPβ was bound to both site-Journal of Neuroinflammation 2009, 6:12 http://www.jneuroinflammation.com/content/6/1/12
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2 and site-3, and was not significantly modified by LPS;
however in the presence of NA there was a clear increase
in C/EBPβ at site-2. Although C/EBPβ is generally consid-
ered to be pro-inflammatory, as indicated above there are
also studies showing that it can suppress transcription. C/
EBPβ represses activation of the cyclin D promoter [26];
and activation of c-Myc expression in Tcells [27].
Sequential immunoprecipitation experiments showing
both C/EBPβ and SUMO-1 interacting at the C/EBP-3 site
suggest that the SUMOylated factor at this site may be C/
EBPβ. The results of Western blots and FRET analysis indi-
cate strongly that C/EBPβ is SUMOylated however these
results may also indicate the presence of a complex con-
taining both C/EBPβ and SUMOylated factor(s). Thus, we
conclude that the suppressive effects of NA on NOS2
expression involve increased SUMOylation at the NOS2
promoter.
Since in this paper we have focused attention on modifi-
cation of C/EBPβ by SUMO-1, our results do not address
the possibility that inflammatory stimuli or NA modify
SUMO-2 or SUMO-3 interactions with the NOS2 pro-
moter or with C/EBPβ, as recently reported to occur in
COS1 cells [26]. Furthermore, in these studies we used an
antibody directed against the amino terminus of C/EBPβ
which does not distinguish between C/EBPβ isoforms;
however findings that C/EBPβ1 is a preferential target for
SUMOylation [26] suggests that our results may primarily
reflect SUMOylation of this isoform.
Conclusion
Our results demonstrate an important role for SUMOyla-
tion in regulating NOS2 expression in astrocytes, and
point to modification of C/EBPβ as a critical determinant.
However, there are likely to be other SUMO targets
involved in the regulation of NOS2 transcription which
may also contribute to suppressive effects of NA which
need to be characterized. In view of the known involve-
ment of NOS2 in a variety of neurological diseases and
conditions, the knowledge that increasing SUMOylation
processes can reduce NOS2 expression provides novel tar-
gets for therapeutic interventions.
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